钆塞酸增强MRI定性及定量评估鉴别不典型局灶性结节性增生与肝细胞腺瘤亚型
回顾性纳入2010年1月至2020年12月经病理证实的29个不典型局灶性结节性增生和90个肝细胞腺瘤,评估钆塞酸增强MRI定性特征及病灶-肝对比增强比(LLCER)。肝胆期等/高信号和LLCER可可靠鉴别不典型局灶性结节性增生与多数肝细胞腺瘤亚型,但β-HCA重叠,决策树分析验证。
要点
- 肝胆期等/高信号见于72.4%(21/29)不典型局灶性结节性增生,β-HCA为71.4%(5/7),两者重叠(p=0.17)。
- 均匀等/高信号和环状强化在不典型局灶性结节性增生中分别占48.3%(14/29)和20.7%(6/29),β-HCA均缺如(p=0.004)。
- LLCER鉴别不典型局灶性结节性增生与U-HCA、H-HCA、I-HCA的AUC为0.91-0.99,敏感度82.8-96.6%,特异度90.0-100%。
核心结论
- 肝胆期等/高信号和LLCER可可靠鉴别不典型局灶性结节性增生与多数肝细胞腺瘤亚型,但β-HCA除外,决策树分析验证;均匀等/高信号或环状强化在β-HCA中缺如,有助于鉴别。
研究设计与样本
- 回顾性研究纳入2010年1月至2020年12月经组织病理学证实的不典型局灶性结节性增生和肝细胞腺瘤患者,共86例(41±11岁;64例女性),含29个不典型局灶性结节性增生和90个肝细胞腺瘤,行钆塞酸增强MRI,两名放射科医师评估定性特征并计算LLCER。
关键影像表现/征象
- 肝胆期等/高信号见于72.4%(21/29)不典型局灶性结节性增生、28.8%(15/52)U-HCA、35%(7/20)I-HCA、0%(0/11)H-HCA和71.4%(5/7)β-HCA。
- 均匀等/高信号见于48.3%(14/29)不典型局灶性结节性增生,β-HCA中缺如(p=0.004)。
- 环状强化见于20.7%(6/29)不典型局灶性结节性增生,β-HCA中缺如(p=0.004)。
诊断标准与关键数值
- LLCER鉴别不典型局灶性结节性增生与U-HCA、H-HCA、I-HCA的AUC为0.91-0.99,敏感度82.8-96.6%,特异度90.0-100%。
- LLCER鉴别不典型局灶性结节性增生与β-HCA的AUC为0.62-0.64,特异度57.1%。
- 肝胆期等/高信号的肝细胞腺瘤中,74.1% LLCER为负值,25.9%(多为β-HCA/U-HCA)为正值(真性强化)。
- 联合决策树以LLCER为主要节点,下游纳入肝胆期特征,但β-HCA仅使用定性特征。
临床应用与阅片要点
- 阅片时注意肝胆期等/高信号在不典型局灶性结节性增生与β-HCA间存在重叠(p=0.17)。
- 均匀等/高信号或环状强化在不典型局灶性结节性增生中可见,在β-HCA中缺如,可助鉴别。
- LLCER有助于区分无真性肝胆期摄取的肝细胞腺瘤与不典型局灶性结节性增生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess qualitative and quantitative imaging features, including lesion-to-liver contrast enhancement ratio (LLCER), on gadoxetic acid-enhanced MRI for differentiating atypical focal nodular hyperplasia (aFNH) from hepatocellular adenoma (HCA) subtypes.
MATERIALS AND METHODS: This retrospective study included patients with histopathologically-confirmed aFNH and HCA who underwent gadoxetic acid-enhanced MRI between January 2010 and December 2020. Two radiologists assessed qualitative imaging features and calculated LLCERs for quantitative evaluation of HBP enhancement. Statistical analyses included ROC curves, sensitivity, specificity, and a decision tree.
RESULTS: 86 patients (41 ± 11 years; 64 women) had 29 aFNHs and 90 HCAs. HBP iso-/hyperintensity was observed in 72.4% (21/29) of aFNH compared to 28.8% (15/52) of U-HCA, 35% (7/20) of I-HCA, and 0% (0/11) of H-HCA. β-HCA showed 71.4% (5/7) iso-/hyperintensity, overlapping with aFNH (p = 0.17). Homogeneous iso-/hyperintensity and rim-like enhancement were present in 48.3% (14/29) and 20.7% (6/29) of aFNH but absent in β-HCA (p = 0.004). LLCER demonstrated high diagnostic performance, differentiating aFNH from U-HCA, H-HCA, and I-HCA(AUCs 0.91-0.99, sensitivities 82.8-96.6%, specificities 90.0-100%). For β-HCA, LLCER showed overlap with aFNH; AUCs (0.62-0.64) and specificities (57.1%). Among HCAs with HBP iso-/hyperintensity, 74.1% had negative LLCER values, while 25.9% (mostly β-HCA/U-HCA) showed positive values (true enhancement). Combined decision trees selected LLCER as the primary node, with downstream HBP features variably incorporated, except β-HCA, which solely used qualitative features.
CONCLUSION: HBP iso-/hyperintensity and LLCER reliably differentiated aFNH from most HCA subtypes, except β-HCA, validated by decision tree analyses. Homogeneous iso-/hyperintensity or rim-like enhancement was absent in β-HCA, aiding differentiation.
KEY POINTS: Question Variability in hepatobiliary phase (HBP) enhancement among hepatocellular adenoma (HCA) subtypes and atypical FNH (aFNH) poses diagnostic challenges. Findings Despite HBP enhancement overlap in aFNH/β-HCA, "homogeneous" and rim-like enhancement aided aFNH differentiation from HCAs. LLCER separated HCAs lacking true HBP uptake from aFNH. Clinical relevance This study explored challenges in differentiating aFNH from HCA subtypes, especially overlapping β-HCA, highlighting discriminatory qualitative markers and quantitative assessment to distinguish true HBP enhancement, an approach validated by decision tree analysis.
引用
- Elbanna KY, Khalili K, AlMoharb M, et al. Qualitative and quantitative assessment of gadoxetic acid MRI in distinguishing atypical focal nodular hyperplasia from hepatocellular adenoma subtypes. Eur Radiol. 2025. PMID: 40369264. doi:10.1007/s00330-025-11679-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。